引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 21次   下载 9  
精神分裂症患者及超高危人群血浆多巴胺β羟化酶活性研究
孙作厘  薄奇静  刘敏  贺毅  王传跃  
0
()
摘要:
目的 探讨精神分裂症患者以及临床超高危人群血浆多巴胺 β 羟化酶(DβH)活性的变 化及其与精神症状的关系。方法 采用横断面成组设计研究方法,选取 2015 年 1 月至 2017 年 12 月在 首都医科大学附属北京安定医院就诊的 61 例首发精神分裂症患者、35 例临床超高危人群以及性别匹配 的 86 名健康对照者作为研究对象。为了分析长期服用抗精神病药对血浆 DβH 的影响,本研究同时纳 入 39 例慢性精神分裂症患者。采用阳性和阴性精神症状评定量表(PANSS)评估患者的精神病性症状, 采用高效液相相色谱 - 电化学的方法检测受试者的血浆 DβH 活性,分析各组血浆 DβH 活性以及与精 神病性症状的关系,并进一步比较首发未用药精神分裂症以及慢性用药患者的血浆 DβH 活性差异,分 析抗精神病药对患者血浆 DβH 活性的影响。结果 首发精神分裂症组、临床超高危组以及健康对照 组的血浆 DβH 活性分别为(12.35±8.55)、(19.59±13.95)、(17.51±11.04)nmol/(ml·min),组间比较差异有 统计学意义(F=6.591,P=0.002);首发精神分裂症组的血浆 DβH 活性低于健康对照组和临床超高危组, 差异有统计学意义(P< 0.05),但临床超高危组和健康对照组比较,差异无统计学意义(P> 0.05)。首发 精神分裂症患者的血浆 DβH 活性与病程、阳性症状、阴性症状及一般精神病性症状间均无相关性(P> 0.05)。首发未用药患者的血浆 DβH 活性低于首发已用药患者,差异有统计学意义(t=2.023,P=0.048)。 慢性用药患者的血浆 DβH 活性为(18.52±7.00)nmol/(ml·min),高于首发未用药患者,差异有统计学意 义(F=7.053,P=0.010)。结论 首发未用药精神分裂症患者的血浆 DβH 活性降低,而短期或长期服用 抗精神病药能够增加患者的血浆 DβH 活性。
关键词:  精神分裂症  多巴胺 β 羟化酶  抗精神病药
DOI:10.3969/j.issn.1009-6574.2022.06.004
基金项目:国家自然科学基金(81971250、81471365);北京市自然科学基金(7192081);国家科技重 大专项(2018ZX09201014)
Study on plasma dopamine β hydroxylase activity in patients with schizophrenia and clinical ultrahigh risk individuals
Sun Zuoli,Bo Qijing,Liu Min,He Yi,Wang Chuanyue
()
Abstract:
Objective To investigate the changes of amine β hydroxylase activity (DβH) in patients with schizophrenia and clinical ultra-high risk individuals and its relationship with psychotic symptoms. Methods 61 schizophrenia patients admitted to Beijing Anding Hospital affiliated to Capital Medical University, 35 clinical ultra-high risk participants and 86 sex-matched healthy controls were included in this study, which is designed by the cross-sectional group research method. To analyze the effect of long-term administration of antipsychotics on DβH, 39 patients with chronic schizophrenia were also included. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the psychotic symptoms of the patients. The plasma DβH activity was detected by high performance liquid chromatography and electrochemistry in participants. The differences of plasma DβH activity and psychotic symptoms among first-episode schizophrenia patients, clinical ultra-high risk individuals, and the healthy controls were analyzed. Further comparison of the plasma DβH activity between first-episode untreated schizophrenia patients and chronic treated schizophrenia patients were carried out to analyze the impact of antipsychotics on plasma DβH activity. Results There was a statistically significant difference (F=6.591, P=0.002) in plasma DβH activities among first-episode schizophrenia patients [(12.35±8.55)nmol/(ml·min)], clinical ultra-high risk individuals [(19.59± 13.95) nmol/(ml·min)] and healthy controls [(17.51±11.04) nmol/(ml·min)]. The plasma DβH activity in schizophrenia patients was significantly lower than those of healthy controls (P < 0.05) and the clinical ultrahigh risk individuals (P < 0.01). However, there was no statistically significant difference in plasma DβH activities between clinical ultra-high risk individuals and healthy controls (P> 0.05). No significant correlations were found between plasma DβH activity and course of disease, positive symptoms, negative symptoms, and general psychotic symptoms in schizophrenia patients (P > 0.05). Plasma DβH activity in the first-episode untreated patients was significantly lower than those in the first-episode treated patients (t=2.023, P=0.048) and the chronic treated patients [(18.52±7.00) nmol/(ml·min), F=7.053, P=0.010]. Conclusions Plasma DβH activity in first-episode untreated schizophrenia patients significantly decreased compared with that in the healthy controls. Short-term or long-term treatment of antipsychotics could increase plasma DβH activity in schizophrenia patients.
Key words:  Schizophrenia  Dopamine β hydroxylase  Antipsychotics

用微信扫一扫

用微信扫一扫